The 6th forum has become a record-breaking one by every measure by gathering 18,200 participants from 98 countries. During three thematic day-long sessions on business, government and society, presentations of more than 650 speakers took place.
Within the framework of the forum business program and in the press center 42 agreements were signed, including 24 partnership agreements with the Skolkovo Foundation. Notably some agreements deal with billion ruble infrastructural projects, such as, e.g. deploying the 5G network in Skolkovo, while other ones suggest direct investments of hundred million rubles, such as the agreement between VEB and IIDF amounting to 200 million dollars or the agreement between IBS company and “Skolkovo Venture – IT I” amounting to 100 million rubles.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8210651-open-innovations-2017-record-breaking/
Woman...without
her man ceases to feel, man ceases to love, and man ceases to live. I
wrote this for my sistas who may need a little reassurance that they
are beautiful as the Kreator made them and to not let society influence
their self worth. Yeah, I wrote this for my sistas, but its intention
is out of kommon respect for ALL women. Directed by Edward Osei-Gyimah
and Featuring T-Tru
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The Heart Rhythm Society (HRS), through its efforts during Atrial Fibrillation Awareness Month in September and throughout the year, is working to raise awareness of the increased prevalence of the disease and the associated risk of stroke in patients living with atrial fibrillation (AFib). Today, HRS releases a new public service announcement (PSA) as part of its ongoing work to educate Americans about AFib, the most common heart arrhythmia, and how it increases one’s risk of stroke fivefold. The PSA can be viewed by clicking here.
AFib affects more than three million Americans and it is estimated that 12 to 16 million Americans will have AFib by 2050. AFib occurs when the upper chambers of the heart (the atria) fibrillate, or “quiver,” which causes a rapid, irregular heart rhythm. The normal heart rate for an adult is between 60 and 100 beats every minute. When the heart is experiencing AFib, the atria can beat over 300 times every minute.
To view the multimedia release go to:
http://www.multivu.com/players/English/7312151-heart-rhythm-society-afib-stroke-psa/
A recent survey conducted by DSM Nutritional Products found that 83 percent of adults in the U.S. believe worsening eye health is inevitable with age. What many people don’t realize is that there’s a connection between healthy eyes and proper nutrition, and it goes beyond eating carrots.
According to Dr. Kimberly Reed, optometrist and Ocular Nutrition Society board member, “Incorporating certain nutrients into the diet can support a lifetime of healthy vision and help protect against serious conditions, including cataracts and age-related macular degeneration (AMD). The latter affects more than 2 million Americans and can lead to severe visual impairment.”
To view Multmedia News Release, go to: http://www.multivu.com/players/English/7129751-dsm-nutritional-products-eye-health-survey/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
As the country celebrates the 45th anniversary of Earth Day, Dallas-based nonprofit Earth Day Texas gears up for its fifth annual event. Founded in 2011, the organization expects more than 75,000 attendees during the three-day event.
Earth Day Texas takes place April 24, 25 and 26 at historic Fair Park in Dallas.
Confirmed speakers include Karenna Gore, author and daughter of Al Gore; Bill White, former mayor of Houston; David Yarnold, president of the Audubon Society; Dan Patrick, Lt. Governor of Texas; B.A. Norrgard, Tiny House advocate; Laura Turner Seydel, chairperson of the Captain Planet Foundation; and Louie Psihoyos, Oscar®-winning director of The Cove.
Seven-time Grammy Award winner Paul Winter will perform on Saturday, April 25, at 4:30 p.m. Grammy nominated artist Michael Martin Murphey will perform on Sunday, April 26, at 4:45 p.m.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7500951-earth-day-texas/
The conference programme will cover the key issues that are of importance to today’s busy IRO, through a range of topical and engaging sessions that will make sure you are right up to date with all the latest thinking. Each session will deliver practical takeaways and there will be a particular emphasis on careers and professional development in IR throughout the conference. With a range of highly engaging breakout sessions to choose from, unparalleled networking opportunities and a showcase of the latest IR services, the 2016 conference promises to be the best yet, an event not to be missed by anyone working in IR.
John Gollifer, General Manager of the IR Society said, “Our annual conference, now in its 30th year, offers a timely opportunity to hear from leading IR practitioners and commentators. We aim to cover the crucial IR issues of the day, as well as offer a great opportunity to meet and share ideas with your peers. We are delighted once again to welcome Evan Davis back as conference host, and where better to be two days before the EU referendum?”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7858751-ir-society-30th-annual-conference-London/
New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, compared to an increase of 8.48 percent in children with asthma not in the program.
“Building Bridges for Asthma Care” is a school-based program designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health’s clinical treatment guidelines. The objectives of the program are addressing the risk of health disparities and asthma-related absenteeism, as well as its related impact on academic achievement for inner city students.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506851-gsk-building-bridges-for-asthma-care/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
